Prab: CSV import

2025-02-15T10:51:48Z

CSV import

← Older revision		Revision as of 10:51, 15 February 2025
Line 1:		Line 1:
	~~'''Zaurategrast''' is a [[pharmaceutical drug]] that was developed for the treatment of [[inflammatory diseases]]. It is a type~~ of ~~[[chemokine receptor antagonist]], specifically targeting~~ the ~~[[CXCR2 receptor]].~~		{{Short description\|An overview of the pharmaceutical compound Zaurategrast}}

	== ~~History~~ ==		==Zaurategrast==
			'''Zaurategrast''' is a pharmaceutical compound that has been studied for its potential therapeutic effects in various medical conditions. It is primarily known for its role as an antagonist of the [[VLA-4]] (Very Late Antigen-4) integrin, which is involved in the adhesion and migration of [[leukocytes]].

	~~Zaurategrast was developed by~~ [[~~GlaxoSmithKline]], a British multinational pharmaceutical company~~. ~~The drug was initially developed to treat [[chronic obstructive pulmonary disease~~]] ~~(COPD), but its use has since been expanded to other inflammatory diseases.~~		[[File:Zaurategrast.svg\|thumb\|right\|Chemical structure of Zaurategrast]]

	== Mechanism of Action ==		===Mechanism of Action===
			Zaurategrast functions by inhibiting the interaction between VLA-4 and its ligand, [[VCAM-1]] (Vascular Cell Adhesion Molecule-1). This interaction is crucial for the transmigration of leukocytes across the endothelium, a process that is significant in the pathogenesis of inflammatory diseases. By blocking this pathway, Zaurategrast can potentially reduce inflammation and tissue damage.

	Zaurategrast ~~works by blocking the CXCR2 receptor. This receptor is found on the surface of certain~~ [[~~white blood cells~~]], ~~and is involved in the body's inflammatory response. By blocking this receptor~~, ~~Zaurategrast can reduce inflammation~~ and ~~alleviate symptoms of inflammatory~~ diseases.		===Therapeutic Applications===
			Zaurategrast has been investigated for its potential use in treating conditions such as [[multiple sclerosis]], [[asthma]], and other autoimmune diseases. Its ability to modulate immune cell trafficking makes it a candidate for therapies aimed at reducing inappropriate immune responses.

	== ~~Clinical Trials~~ ==		===Pharmacokinetics===
			The pharmacokinetic profile of Zaurategrast includes its absorption, distribution, metabolism, and excretion. Understanding these parameters is essential for determining the appropriate dosing regimen and predicting the drug's behavior in the body.

	~~Zaurategrast has undergone several [[~~clinical trials]] to ~~assess its~~ safety ~~and efficacy~~. These ~~trials have shown that the drug is generally well-tolerated, with few side effects. However, more research is needed~~ to ~~fully understand~~ the ~~long-term~~ effects ~~of Zaurategrast~~.		===Clinical Trials===
			Several clinical trials have been conducted to evaluate the efficacy and safety of Zaurategrast in various patient populations. These studies help to establish the therapeutic potential and identify any adverse effects associated with its use.

	== ~~Potential Uses~~ ==		==Related pages==
			* [[Integrin]]
	~~While Zaurategrast was initially developed for COPD, it has potential uses in other inflammatory diseases. These include [[rheumatoid arthritis]], [[psoriasis]], and~~ [[~~inflammatory bowel disease~~]]~~. However, further research is needed to confirm the efficacy of Zaurategrast in these conditions.~~		* [[Leukocyte]]
			* [[Autoimmune disease]]
	~~== See Also ==~~		* [[Inflammation]]

	* [[~~Chemokine receptor antagonist~~]]
	* [[~~GlaxoSmithKline~~]]
	* [[~~Inflammatory diseases~~]]

	~~== References ==~~

	~~<references />~~

	[[Category:Pharmaceutical drugs]]		[[Category:Pharmaceutical drugs]]
	[[Category:~~Inflammatory diseases~~]]		[[Category:Immunology]]
	~~[[Category:GlaxoSmithKline]]~~
	~~{{Pharma-stub}}~~

Prab: CSV import

2024-03-02T16:56:49Z

CSV import

New page

'''Zaurategrast''' is a [[pharmaceutical drug]] that was developed for the treatment of [[inflammatory diseases]]. It is a type of [[chemokine receptor antagonist]], specifically targeting the [[CXCR2 receptor]].

== History ==

Zaurategrast was developed by [[GlaxoSmithKline]], a British multinational pharmaceutical company. The drug was initially developed to treat [[chronic obstructive pulmonary disease]] (COPD), but its use has since been expanded to other inflammatory diseases.

== Mechanism of Action ==

Zaurategrast works by blocking the CXCR2 receptor. This receptor is found on the surface of certain [[white blood cells]], and is involved in the body's inflammatory response. By blocking this receptor, Zaurategrast can reduce inflammation and alleviate symptoms of inflammatory diseases.

== Clinical Trials ==

Zaurategrast has undergone several [[clinical trials]] to assess its safety and efficacy. These trials have shown that the drug is generally well-tolerated, with few side effects. However, more research is needed to fully understand the long-term effects of Zaurategrast.

== Potential Uses ==

While Zaurategrast was initially developed for COPD, it has potential uses in other inflammatory diseases. These include [[rheumatoid arthritis]], [[psoriasis]], and [[inflammatory bowel disease]]. However, further research is needed to confirm the efficacy of Zaurategrast in these conditions.

== See Also ==

* [[Chemokine receptor antagonist]]
* [[GlaxoSmithKline]]
* [[Inflammatory diseases]]

== References ==

<references />

[[Category:Pharmaceutical drugs]]
[[Category:Inflammatory diseases]]
[[Category:GlaxoSmithKline]]
{{Pharma-stub}}

Zaurategrast - Revision history

Prab: CSV import

Prab: CSV import